J Rheumatol:HLA-DRB1等位基因作为皮肌炎抗MDA5抗体发展的遗传危险因素

2017-07-17 xiangting MedSci原创

对DM中DRB1 * 04:01和* 12:02赋予了对抗MDA5抗体产生的易感性,这不能用SE假说解释。

表达抗黑素瘤分化相关蛋白5(抗MDA5)抗体的多发性肌炎/皮肌炎(PM / DM)患者,经常存在间质性肺病(ILD)。这项研究的目的是探讨在PM/DM中HLA-DRB1与抗MDA5表达的关系。

比较了70例PM患者,104例DM患者和汉族人群中400例健康对照者的DRB1等位基因频率。

DRB1 * 04:01 [17.0%vs 1.3%,校正p值(p c)= 3.8×10 -8,OR 16.2,95%CI 6.6-39.7]和* 12:02(42.6%vs.19.3% ,p c  = 0.008,OR 3.1,95%CI 1.7-5.7)的频率在抗MDA5阳性的PM / DM患者中显著高于对照组。DRB1 * 04:01 的频率(p = 5.2×10 -6,OR 17.1,95%CI 5.3-54.9)和* 12:02(p = 3.8×10 -4,OR 3.1,95%CI 1.7-5.7 )在抗MDA5阳性的DM-ILD的患者中高于对照组,而DRB1 * 04:01和* 12:02的频率在抗MDA5阴性的DM-ILD的患者和对照组间没有差异。在对照组和按抗MDA5和ILD是否存在分层的DM患者之间,DRB1等位基因频率没有差异,除了携带"共享表位"(SE)的* 04:01,即* 01:01,* 01:02,* 04:05和* 10:01。

对DM中DRB1 * 04:01和* 12:02赋予了对抗MDA5抗体产生的易感性,这不能用SE假说解释。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-18 w984445tii
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-11-05 wetgdt
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-19 marongnuan
  7. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-18 虈亣靌

    学习了很多很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-17 天涯183

    非常好的文章,学习了,很受益

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2063777, encodeId=976f2063e7778, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jul 18 05:21:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943543, encodeId=eb8a1943543b2, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Nov 05 21:21:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997673, encodeId=3338199e67376, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Mon Jul 24 14:21:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309262, encodeId=f2e91309262c7, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484139, encodeId=3ce5148413969, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502029, encodeId=31e3150202924, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631237, encodeId=ec28163123e37, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Wed Jul 19 02:21:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223560, encodeId=170b223560d1, content=学习了很多很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jul 18 13:34:42 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223250, encodeId=5bab223250dd, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jul 17 15:29:40 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223244, encodeId=406e223244a7, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Jul 17 14:48:00 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-17 dhzzm

    学习了分享了

    0

相关资讯

NEJM:罕见炎性肌病-案例报道

患者男,47岁,因左眼和喉咙肿胀感3天急诊就诊。现病史:3天前,患者开始出现吞咽固体困难,觉得好像食物卡在了喉咙里。不伴瘙痒、畏光、复视、头痛、视力改变和疼痛。声音嘶哑,不伴喘息和呼吸急促。病程中也没有发烧、疲劳、胃肠道症状和其他不适。既往史、个人史:患者既往高血压史。对贝类过敏。没有使用处方药,近一个月也没有使用新的非处方药。他从事房地产开发工作,独自生活在波士顿。在过去的3年里,他曾到过中

NEJM:弥漫性软组织钙化

一名50岁的患有进行性皮肌炎的妇女来院就诊,在其手臂和腿部可见明显的弥漫性皮下结节(如图A所示)。在20年前,该妇女曾被诊断患有皮肌炎,其中包括炎性肌病、Gottron丘疹和光敏性皮疹。虽然采用甲氨蝶呤和强的松进行治疗使病情得以缓解,但她的皮肌炎一直处于活动期,并逐渐发展为移动困难和无痛性皮下结节。血液学检查结果显示,其血清钙、磷、白蛋白、25-羟基维生素D和甲状旁腺激素的血清水平均正常。左肩(如

BMJ:一例因肌肉无力、吞咽困难就诊案例报道

患者女,29岁,因肌肉无力、吞咽困难就诊。查体:如图1,上眼睑肿胀,且周围呈紫红色。手指背侧布满爆发性红斑。图2示患者的双侧胸锁乳突肌皮肤有对称的紫色斑片。患者的手臂很难举过头顶。辅助检查:血常规未见明显异常,肌酸激酶1577 U/L(参考范围:30-135)。患者诊断:急性皮肌炎(伴向阳性皮疹)皮肌炎以近端肌肉无力和肌肉炎症为主要表现。皮肌炎与多发性肌炎不同,该疾病会出现多种皮肤表现,比如本案例

Lancet:治疗新发性青少年皮肌炎——泼尼松加甲氨蝶呤更有效

大多数治疗青少年皮肌炎的数据都来自传闻,而非随机病例系列。

什么是皮肌炎?如何处理?

皮肌炎是导致肌肉无力和皮疹的医疗状况。 根据约翰·霍普金斯肌炎中心,女性患有皮肌炎的概率是男性的两倍。 虽然没有治愈的条件,一些治疗可以帮助最小化症状。

HFSA 2016:多发性肌炎和皮肌炎患者,警惕心衰!

HFSA年会上的数据显示:多发性肌炎和皮肌炎患者的心血管危险因素和心衰发病率增加。 研究人员写道,虽然这一人群中传统的心血管危险因素明显增加,但是这些因素对心衰的发展会有什么影响? 研究人员多48502820例患者进行了回顾性分析,使用多机构的数据库,调查这类多发性肌炎和皮肌炎患者的心血管危险因素和心衰发病率等情况。 队列中多发性肌炎和皮肌炎分别有5980(0.012%)例和10